Lead Intoxication
- 1 December 1986
- journal article
- review article
- Published by Springer Nature in Medical Toxicology
- Vol. 1 (6) , 387-410
- https://doi.org/10.1007/bf03259851
Abstract
Lead intoxication was recognised as early as 2000 BC and the widespread use of lead has been a cause of endemic chronic plumbism in several societies throughout history. In the twentieth century, lead intoxication is still a common problem. In children it is largely due to ingestion of pica and environmental exposure, whereas adult groups at greatest risk are the industrially exposed: thus, screening of these workers should be undertaken at regular intervals. The clinical features of lead intoxication are nonspecific and often go unrecognised. The early manifestations are largely neuropsychiatric, followed by more significant disturbances of the central and peripheral nervous systems, symptomatic gastrointestinal, musculoskeletal, haematological and endocrine abnormalities. The association of lead poisoning with renal disease is well documented and must be considered, particularly if there is associated hypertension and/or gout. Blood lead concentrations are an unreliable predictor of body lead stores as they are indicative only of recent exposure. Haematological parameters have been used to assess those at risk of toxicity, but although more reliable than blood concentrations, they also fail to predict those patients at risk of toxicity. The recommended assessment for patients with suspected lead intoxication is a calcium disodium edetate chelation test, which is a sensitive marker for assessing body stores and subsequent intoxication. In children the dosage should be 50 mg/kg up to 1000mg, and in adults 1000mg administered intravenously or 2000mg intramuscularly in divided doses 12 hours apart with subsequent 72 hour urinary lead estimations. Lead excretion levels greater than 350 μg/72 hours should be considered as suggestive of intoxication, particularly if supported by historical, clinical or biochemical evidence of lead exposure. Treatment of patients with positive chelation tests involves symptomatic treatment and a course of chelation therapy utilising calcium disodium edetate in doses similar to those used for testing, and in the more severely intoxicated patient, the addition of dimercaprol in doses of 75 mg/m2 every 4 hours to a total of 300 mg/m2/day. The safety of these treatment regimens is well documented.Keywords
This publication has 100 references indexed in Scilit:
- Management of childhood lead poisoningThe Journal of Pediatrics, 1984
- Assessment of lead stores in children: Validation of an 8-hour CaNa2EDTA provocative testThe Journal of Pediatrics, 1984
- Contribution of Lead to Hypertension with Renal ImpairmentNew England Journal of Medicine, 1983
- Saturnine Gout among Roman AristocratsNew England Journal of Medicine, 1983
- National Estimates of Blood Lead Levels: United States, 1976–1980New England Journal of Medicine, 1982
- The Role of Lead in Gout NephropathyNew England Journal of Medicine, 1981
- Reduction in 1,25-Dihydroxyvitamin D in Children with Increased Lead AbsorptionNew England Journal of Medicine, 1980
- Deficits in Psychologic and Classroom Performance of Children with Elevated Dentine Lead LevelsNew England Journal of Medicine, 1979
- Preventing lead poisoning in young children: A statement by the center for disease controlThe Journal of Pediatrics, 1978
- The use of chelating agents in the treatment of acute and chronic lead intoxication in childhoodThe Journal of Pediatrics, 1968